This review discusses the evidence in support of the use of lisdexamfetamine dimesilate, its pharmacology including its mechanism of action, and efficacy and tolerability demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Dr Josh Geffen, a Brisbane-based private Psychiatrist at Brisbane’s Toowong Specialist Clinic and the Medical Director of ECT at the Toowong Private Hospital and Dr Urvashnee Singh, a psychiatrist and the clinical lead of the inpatient Eating Disorder program.
Please login below to download this issue (PDF)